Valuation: Theracryf Plc

Market Cap 6.2M 5.42M 5M 4.62M 8.77M 591M 8.91M 59.77M 23.47M 291M 23.28M 22.77M 1B P/E 2026 *
-1.45x
P/E 2027 * -1.77x
Enterprise Value 4.05M 3.54M 3.27M 3.02M 5.73M 386M 5.82M 39.04M 15.33M 190M 15.2M 14.87M 654M EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
54.35%
Yield 2026 *
-
Yield 2027 * -
1 month-12.24%
3 months+10.26%
6 months+2.38%
Current year+7.50%
1 week 0.21
Extreme 0.21
0.22
1 month 0.21
Extreme 0.21
0.25
Current year 0.18
Extreme 0.182
0.27
1 year 0.18
Extreme 0.175
0.3
3 years 0.18
Extreme 0.175
3.4
5 years 0.18
Extreme 0.175
9
10 years 0.18
Extreme 0.175
35
Manager TitleAgeSince
Chief Executive Officer 64 30/09/2020
Director of Finance/CFO - 04/09/2023
Chief Tech/Sci/R&D Officer - 30/04/2021
Director TitleAgeSince
Director/Board Member - 13/10/2015
Director/Board Member 64 30/09/2020
Director/Board Member - 31/12/2023
Date Insider Type Main position Quantity % Market Cap.
15/10/25
Tracarta Ltd.
BuyCompany 7,342,296 0.3448%
21/05/25Others

Director

422,727,272 19.8499%
03/03/25Buy

Chief Operating Officer

1,500,000 0.2945%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-15.69%-92.83% 6.2M
-4.14%-8.06%+57.35%+117.24% 54.63B
+1.84%-0.66%+75.79%+93.87% 54.88B
-2.24%+3.59%+19.60%+466.72% 25.06B
-1.60%-6.21%-19.69%-14.84% 23.14B
+2.43%+1.06%+47.70%-0.11% 19.88B
-3.19%0.00%+33.99%-26.87% 17.55B
-6.84%+2.18%+195.12%+357.18% 16.5B
-1.05%+1.16%+25.08%+196.28% 14.2B
+8.74%+3.51%+53.81% - 15.36B
Average -0.61%-0.25%+47.31%+121.85% 24.12B
Weighted average by Cap. -0.91%-1.46%+55.04%+137.78%

Financials

2026 *2027 *
Net sales - -
Net income -3.35M -2.93M -2.7M -2.5M -4.74M -320M -4.82M -32.3M -12.69M -157M -12.58M -12.31M -541M -3.43M -3M -2.77M -2.56M -4.85M -327M -4.93M -33.06M -12.98M -161M -12.88M -12.6M -554M
Net Debt -2.15M -1.88M -1.74M -1.6M -3.04M -205M -3.09M -20.73M -8.14M -101M -8.08M -7.9M -347M 453K 397K 366K 338K 641K 43.25M 652K 4.37M 1.72M 21.31M 1.7M 1.67M 73.24M
Logo Theracryf Plc
TheraCryf plc is a clinical-stage drug development company focusing on brain disorders. The Company has a clinical and preclinical pipeline of indications, including addiction, anxiety, fatigue, narcolepsy, glioblastoma and neurodevelopmental disorders. Its lead program, orexin-1 antagonist, is being developed towards the clinic to target addictive behaviors like binge eating disorder (BED). It is also advancing a clinical-stage asset, SFX-01, in the fatal brain cancer glioblastoma (GBM). SFX-01 is a patented form of sulforaphane which has shown potential in the treatment of various cancers, neurodevelopmental disorders and other diseases. It has licensed the global rights for SFX-01 in neurodevelopmental disorders and schizophrenia to Stalicla. The Company also has a candidate molecule dopamine active transport (DAT) inhibitor at a late preclinical stage targeting fatigue and narcolepsy.
Employees
9
Date Price Change Volume
10/07/26 GBX 0.2150 0.00% 243,057
09/07/26 GBX 0.2150 0.00% 2,037,924
08/07/26 GBX 0.2150 0.00% 0
07/07/26 GBX 0.2150 0.00% 554,117
06/07/26 GBX 0.2150 0.00% 921,129
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.002885USD
Average target price
0.0431USD
Spread / Average Target
+1,395.17%

Annual profits - Rate of surprise